DEADLINE APPROACHING: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors To Inquire About A Securities Fraud Class Action By October 6, 2025
Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .
Altimmune, headquartered in Gaithersburg, Maryland, is a clinical-stage biopharmaceutical company.
The lawsuit alleges that on June 26, 2025, Altimmune announced that its IMPACT study had failed to achieve statistical significance in the trial's primary endpoint of fibrosis reduction, citing a higher-than-expected placebo response. Despite management's prior optimistic statements, the Company downplayed the poor results, attributing the outcome to the Phase 2 nature of the trial and suggesting improvements in a future Phase 3 study.
Following this disclosure, Altimmune's stock plunged 53% , from a close of $7.71 per share on June 25, 2025, to a close of $3.61 on June 26, 2025, causing heavy losses for investors.
If you are an Altimmune investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at ... or (215) 875-3015, or Caitlin Adorni at ... or (267)764-4865.
About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
...
Caitlin Adorni
Berger Montague
(267) 764-4865
...


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Seoul Exchange, One Of Only Two Licensed Platforms For Unlisted Securities, Will Exclusively Use Story To Settle Tokenized Rwas
- Phase 6 Reaches 50% Mark As Mutuum Finance (MUTM) Approaches Next Price Step
- 0G Labs Launches Aristotle Mainnet With Largest Day-One Ecosystem For Decentralized AI
- Solotto Launches As Solana's First-Ever Community-Powered On-Chain Lottery
- Kintsu Launches Shype On Hyperliquid
- Blockchainfx Raises $7.24M In Presale As First Multi-Asset Super App Connecting Crypto, Stocks, And Forex Goes Live In Beta
Comments
No comment